Clinical Trial Updates, Appointments, FDA Acknowledgments and Qualifications - Research Report on Novartis, Endo, The Medicines Company, United Therapeutics, and Forest

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, September 17, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Novartis AG (NYSE: NVS), Endo Health Solutions Inc. (NASDAQ: ENDP), The Medicines Company (NASDAQ: MDCO), United Therapeutics Corporation (NASDAQ: UTHR), and Forest Laboratories, Inc. (NYSE: FRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Novartis AG Research Report

On September 8, 2013, Novartis AG (Novartis) announced new analyses of data for once-daily Ultibro Breezhaler (investigational QVA149), which showed significant improvements in lung function, shortness of breath, and health-related quality of life for chronic obstructive pulmonary disease (COPD) patients, versus all comparators. "Novartis is pleased that these new analyses further support that the efficacy of dual therapy, which has the potential to make a real difference to peoples' lives," said Tim Wright, Head of Development at Novartis Pharmaceuticals. According to Novartis, investigational QVA149 is currently being assessed in a clinical trial program involving over 10,000 patients, and in July 2013, it received a positive opinion for approval from the European Medicine Agency's (EMA) Committee for the Human use of Medicinal Products (CHMP) as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD. The Full Research Report on Novartis AG - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []


Endo Health Solutions Inc. Research Report

On September 9, 2013, Endo Health Solutions Inc. (Endo) announced the appointment of Suketu Upadhyay as the Company's Executive Vice President and CFO, effective September 23, 2013. Prior to joining Endo, Upadhyay served at Becton, Dickinson & Company's (BD) as the Principal Accounting Officer and interim CFO. Rajiv De Silva, President and CEO of Endo said, "He brings significant healthcare industry experience and a track record of delivering value that will be instrumental in the execution of our new growth strategy. His breadth of experience will be an asset to the company as we chart our course forward." The Full Research Report on Endo Health Solutions Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []


The Medicines Company Research Report

On September 10, 2013, The Medicines Company announced the results for its Phase 3 SOLO clinical trial program of oritavancin, which is currently under investigation for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria. Ralph Corey MD, Professor of Medicine and Infectious Disease at Duke University and Principal Investigator of the SOLO trials said, "What is unique about this study is it is testing an antibiotic where the full course of treatment has been given to the patient through one administration. This study shows that a single 1200 mg dose of oritavancin was non inferior to 7 to 10 days of vancomycin in treating ABSSSI caused by gram-positive pathogens including methicillin-resistant Staphylococcus aureus, MRSA." The Company informed that all protocol-specified primary and secondary efficacy endpoints were met in both SOLO I and SOLO II trials. The Full Research Report on The Medicines Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []


United Therapeutics Corporation Research Report

On September 11, 2013, United Therapeutics Corporation (United Therapeutics) announced that the FDA has acknowledged its resubmission of the NDA for treprostinil diolamine extended release tablets (oral treprostinil) for the treatment of pulmonary arterial hypertension. The Company informed that the FDA has classified the NDA resubmission as a complete, class 2 response to its March 22, 2013 complete response letter, and has set a user fee goal date of February 16, 2014. The Full Research Report on United Therapeutics Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []


Forest Laboratories, Inc. Research Report

On September 12, 2013, Forest Laboratories, Inc. (Forest) announced that the FDA has designated its investigational drug, ceftazidime/avibactam, as a qualified infectious disease product (QIDP). The Company informed that ceftazidime/avibactam is currently in Phase III trials to investigate efficacy in treating hospitalized patients with complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI). The investigational drug has received QIDP designation for complicated intra-abdominal infections (cIAI), complicated urinary tract infections (cUTI) and hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia (HABP/VABP). The Full Research Report on Forest Laboratories, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []



  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by an analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
  5. For any urgent concerns or inquiries, please contact us at [email protected].
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.


Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Investors' Reports